David M. Berman

David M. Berman

Auto-generated profile, based on publicly available information

David M. Berman

Department of Pathology and Molecular Medicine Queen's University Kingston Ontario Canada

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2004 in Nature
Verified
Journal Article
Closed access
PBPhilip A. Beachy
Philip A. Beachy
Sunil KarhadkarSunil Karhadkar
Sunil Karhadkar
DBDavid M. Berman
David M. Berman

30 August 2002 in Science
Verified
Journal Article
Closed access
PDF file
DBDavid M. Berman
David M. Berman
Sunil KarhadkarSunil Karhadkar
Sunil Karhadkar
AHAndrew R. Hallahan
Andrew R. Hallahan
JPJoel I. Pritchard
Joel I. Pritchard
CECharles G. Eberhart
Charles G. Eberhart
PBPhilip A. Beachy
Philip A. Beachy
Constitutive Hedgehog (Hh) pathway activity is associated with initiation of neoplasia, but its role in the continued growth of established tumors is unclear. Here, we investigate the therapeutic efficacy of the Hh pathway antagonist cyclopamine in preclinical models of medulloblastoma, the most common malignant brain tumor in children. Cyclopamine treatment of murine medulloblastoma cells blocked proliferation in vitro and induced changes in gene expression consistent with initiation of neuronal differentiation and loss of neuronal stem cell–like character. This compound also caused regression of murine tumor allografts in vivo and induced rapid death of cells from freshly resected human medulloblastomas, but not from other brain tumors, thus establishing a specific role for Hh pathway activity in medulloblastoma growth.

20 February 2018 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
TJTamara Jamaspishvili
Tamara Jamaspishvili
DBDavid M. Berman
David M. Berman
ARAshley E. Ross
Ashley E. Ross
HSHoward I. Scher
Howard I. Scher
AMAngelo M. De Marzo
Angelo M. De Marzo
TLTamara L. Lotan
Tamara L. Lotan

1 March 2019 in Cancer Cell
Verified
Journal Article
Closed access
ASAnkit Sinha
Ankit Sinha
VHVincent Huang
Vincent Huang
JLJulie Livingstone
Julie Livingstone
JWJenny Wang
Jenny Wang
NFNatalie S. Fox
Natalie S. Fox
PBPaul C. Boutros
Paul C. Boutros

1 May 2007 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
MZMarianna Zahurak
Marianna Zahurak
GPGiovanni Parmigiani
Giovanni Parmigiani
WYWayne Yu
Wayne Yu
RSRobert B Scharpf
Robert B Scharpf
DBDavid Berman
David Berman
LCLeslie Cope
Leslie Cope
Pre-processing methods for two-sample long oligonucleotide arrays, specifically the Agilent technology, have not been extensively studied. The goal of this study is to quantify some of the sources of error that affect measurement of expression using Agilent arrays and to compare Agilent's Feature Extraction software with pre-processing methods that have become the standard for normalization of cDNA arrays. These include log transformation followed by loess normalization with or without background subtraction and often a between array scale normalization procedure. The larger goal is to define best study design and pre-processing practices for Agilent arrays, and we offer some suggestions.

1 October 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
WKWolfram Kleeberger
Wolfram Kleeberger
GBG. Steven Bova
G. Steven Bova
MNMatthew E. Nielsen
Matthew E. Nielsen
MHMehsati Herawi
Mehsati Herawi
ACAi-Ying Chuang
Ai-Ying Chuang
DBDavid M. Berman
David M. Berman
The intermediate filament protein Nestin identifies stem/progenitor cells in adult tissues, but the function of Nestin is poorly understood. We investigated Nestin expression and function in common lethal cancers. Nestin mRNA was detected in cell lines from small cell lung, and breast cancers, and particularly elevated in cell lines derived from prostate cancer metastases. Whereas the androgen-independent lines PC3, 22RV1, and DU145 all expressed Nestin transcripts under standard culture conditions, the androgen-dependent line LnCaP expressed Nestin only on androgen withdrawal. We confirmed associations of Nestin expression, androgen withdrawal, and metastatic potential by immunohistochemical analysis of samples from 254 prostate cancer patients. Cytoplasmic Nestin protein was readily identifiable in prostate cancer cells from 75% of patients with lethal androgen-independent disease, even in cancer sampled from the prostate itself. However, Nestin expression was undetectable in localized androgen-deprived tumors and in metastases without prior androgen deprivation. To address its function, we reduced Nestin levels with short hairpin RNAs, markedly inhibiting in vitro migration and invasion in prostate cancer cells but leaving cell growth intact. Nestin knockdown also diminished metastases 5-fold compared with controls despite uncompromised tumorigenicity at the site of inoculation. These results specify a function for Nestin in cell motility and identify a novel pathway for prostate cancer metastasis. Activity of this pathway may be selected by the extraprostatic environment or, as supported by our data, may originate within the prostate after androgen deprivation. Further dissection of this novel Nestin migration pathway may lead to strategies to prevent and neutralize metastatic spread. [Cancer Res 2007;67(19):9199–206]